Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZAP MS: Zenapax in Multiple Sclerosis
NCT00071838Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Oct 2003
- Primary completion
- Oct 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daclizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by National Institute of Neurological Disorders and Stroke. Started Oct 2003; status: completed.
02
Drugs
daclizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00071838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071838.